News: Umeå, 9 August 2022. Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming conferences.
LSX Nordic, Copenhagen, Denmark, 6-7 September
Biostock Investerarevent, digital, 14 September
Nordic Life Science Days, Malmö, Sweden, 28-29 September
Bio-Europe, Leipzig, Germany, 24-26 October
Redeye Life Science Day, Stockholm, Sweden, 24 November
Biostock Life Science Summit, Lund, Sweden, 29-30 November
“I am looking forward to these events. We are approaching clinical trials of our biological lead candidate SOL-116 and industry meetings provide good opportunities to present our progress”, says CEO Einar Pontén.
For further information, please contact:
Einar Pontén, CEO
Mobil: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.